Literature DB >> 27815841

The Ubiquitin Receptor ADRM1 Modulates HAP40-Induced Proteasome Activity.

Zih-Ning Huang1, Lu-Shiun Her2.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an N-terminal expansion of polyglutamine stretch (polyQ) of huntingtin (Htt) protein. HAP40 is a huntingtin-associated protein with unknown cellular functions. Increased HAP40 expression has been reported in the brain of HD patients and HD mouse model. However, the relationship between the elevation of HAP40 and HD etiology remains elusive. In this study, we demonstrated that overexpression of HAP40 enhanced accumulation of mutant Htt aggregates and caused defects in proteasome function. Specifically, excess HAP40 interfered with adhesion-regulating molecule 1 (ADRM1), a proteasome ubiquitin receptor, to regulate the proteasome-dependent pathway. Increasing ADRM1 in the presence of excess HAP40 alleviated mutant Htt aggregates and at the same time, restored the cell viability. Reducing ADRM1 in the absence of excess HAP40; on the other hand, increased mutant Htt aggregates and decreased the cell viability. Our data provide compelling evidence to support that ADRM1 plays an important role in mediating removal of mutant Htt aggregates when excess HAP40 is present. ADRM1-dependent ubiquitin proteasome system (UPS) may be a general mechanism to guard cells from mutant Htt toxicity.

Entities:  

Keywords:  Autophagy; Huntingtin-associated protein; Huntington’s disease (HD); Mutant huntingtin aggregates; Ubiquitin proteasome system; Ubiquitin receptor

Mesh:

Substances:

Year:  2016        PMID: 27815841     DOI: 10.1007/s12035-016-0247-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  94 in total

1.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

2.  Expression of the Huntington's disease (IT15) protein product in HD patients.

Authors:  G Schilling; A H Sharp; S J Loev; M V Wagster; S H Li; O C Stine; C A Ross
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

3.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

4.  Global changes to the ubiquitin system in Huntington's disease.

Authors:  Eric J Bennett; Thomas A Shaler; Ben Woodman; Kwon-Yul Ryu; Tatiana S Zaitseva; Christopher H Becker; Gillian P Bates; Howard Schulman; Ron R Kopito
Journal:  Nature       Date:  2007-08-09       Impact factor: 49.962

5.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.

Authors:  G Schilling; M W Becher; A H Sharp; H A Jinnah; K Duan; J A Kotzuk; H H Slunt; T Ratovitski; J K Cooper; N A Jenkins; N G Copeland; D L Price; C A Ross; D R Borchelt
Journal:  Hum Mol Genet       Date:  1999-03       Impact factor: 6.150

6.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.

Authors:  Ganta Vijay Chaitanya; Alexander J Steven; Phanithi Prakash Babu
Journal:  Cell Commun Signal       Date:  2010-12-22       Impact factor: 5.712

7.  Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death.

Authors:  Katrin Juenemann; Christina Weisse; Denise Reichmann; Christoph Kaether; Cornelis F Calkhoven; Gabriele Schilling
Journal:  Neurotox Res       Date:  2010-11-30       Impact factor: 3.911

8.  Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease.

Authors:  Mark S Hipp; Chetan N Patel; Kirill Bersuker; Brigit E Riley; Stephen E Kaiser; Thomas A Shaler; Michael Brandeis; Ron R Kopito
Journal:  J Cell Biol       Date:  2012-02-27       Impact factor: 10.539

9.  Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin.

Authors:  Hui Yang; Xiaoyan Zhong; Petek Ballar; Shouqing Luo; Yuxian Shen; David C Rubinsztein; Mervyn J Monteiro; Shengyun Fang
Journal:  Exp Cell Res       Date:  2006-11-03       Impact factor: 3.905

10.  Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease.

Authors:  Arun Pal; Fedor Severin; Barbara Lommer; Anna Shevchenko; Marino Zerial
Journal:  J Cell Biol       Date:  2006-02-13       Impact factor: 10.539

View more
  5 in total

1.  Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model.

Authors:  Zih-Ning Huang; Jie-Mao Chen; Liang-Ching Huang; Yi-Hsuan Fang; Lu-Shiun Her
Journal:  Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.590

Review 2.  Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.

Authors:  Neha Sawant; Hallie Morton; Sudhir Kshirsagar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-09-14       Impact factor: 5.590

3.  Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.

Authors:  Nathan Riguet; Anne-Laure Mahul-Mellier; Niran Maharjan; Johannes Burtscher; Marie Croisier; Graham Knott; Janna Hastings; Alice Patin; Veronika Reiterer; Hesso Farhan; Sergey Nasarov; Hilal A Lashuel
Journal:  Nat Commun       Date:  2021-11-12       Impact factor: 14.919

4.  Adhesion Regulating Molecule 1 Mediates HAP40 Overexpression-Induced Mitochondrial Defects.

Authors:  Zih-Ning Huang; Her Min Chung; Su-Chiung Fang; Lu-Shiun Her
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

Review 5.  Huntingtin and Its Partner Huntingtin-Associated Protein 40: Structural and Functional Considerations in Health and Disease.

Authors:  Manuel Seefelder; Fabrice A C Klein; Bernhard Landwehrmeyer; Rubén Fernández-Busnadiego; Stefan Kochanek
Journal:  J Huntingtons Dis       Date:  2022
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.